Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/21754
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2021-09-08T05:44:35Z-
dc.date.available2021-09-08T05:44:35Z-
dc.date.issued2006-
dc.identifier.citationYeşilbursa, D. vd. (2006). ''Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction''. Heart and Vessels, 21(1), 33-37.en_US
dc.identifier.issn0910-8327-
dc.identifier.issn1615-2573-
dc.identifier.urihttps://doi.org/10.1007/s00380-005-0854-4-
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs00380-005-0854-4-
dc.identifier.urihttp://hdl.handle.net/11452/21754-
dc.description.abstractRecent evidence suggests that postischemic myocardial dysfunction ("stunning") may be mediated by oxygen free radicals. Various studies have reported the beneficial effects of antioxidants in ischemia-reperfusion injury. The aim of this study was to assess the effect of N-acetylcysteine (NAC) treatment on oxidative stress, infarct size, and left ventricular (LV) function, as adjunct therapy in myocardial infarction (MI). Patients with acute MI received either 15 g NAC infused over 24 h (n = 15) or no NAC (n = 15), combined with streptokinase. Peripheral venous blood was serially sampled to measure creatine kinase (CK)-MB levels. Plasma malondialdehyde (MDA) level was measured at admission and after 4 and 24h. Echocardiography was performed within 3 days of MI and after 3 months. At admission, plasma MDA levels were not different between the groups. In the NAC-treated patients plasma MDA levels decreased, whereas in the nontreated NAC patients MDA levels increased at 4 and 24h (P < 0.01 and P < 0.001, respectively). Left ventricular ejection fraction was higher (P < 0.05) and LV end-systolic and end-diastolic diameters were lower (P < 0.001 and P < 0.001) in patients receiving NAC on day 3. Left ventricular wall motion score index was significantly lower in patients treated with NAC on day 3 (P < 0.05). Left ventricular diastolic parameters were not different whether patients were treated with NAC or not. No difference in reduction of infarct size was detected between the groups according to CK-MB levels. It was thus demonstrated that administration of NAC in combination with streptokinase significantly diminished oxidative stress and improved LV function in patients with acute MI. These encouraging results would justify the performance of a larger controlled study.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiovascular system & cardiologyen_US
dc.subjectN-Acetylcysteineen_US
dc.subjectMyocardial infarctionen_US
dc.subjectMalondialdehydeen_US
dc.subjectPlasmaen_US
dc.subjectTherapyen_US
dc.subjectReductionen_US
dc.subjectRecanalizationen_US
dc.subjectRecanalizationen_US
dc.subjectNitroglycerinen_US
dc.subjectMalondialdehydeen_US
dc.subjectIschemia-reperfusionen_US
dc.subjectReperfusion injuryen_US
dc.subjectOxygen free-radicalsen_US
dc.subjectFree-radical generationen_US
dc.titleEffect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarctionen_US
dc.typeArticleen_US
dc.identifier.wos000234935000006tr_TR
dc.identifier.scopus2-s2.0-31744434804tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.identifier.startpage33tr_TR
dc.identifier.endpage37tr_TR
dc.identifier.volume21tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalHeart and Vesselsen_US
dc.contributor.buuauthorYeşilbursa, Dilek-
dc.contributor.buuauthorSerdar, Akın-
dc.contributor.buuauthorŞentürk, Sunay-
dc.contributor.buuauthorSerdar, Zehra-
dc.contributor.buuauthorSağ, Saim-
dc.contributor.buuauthorCordan, Jale-
dc.contributor.researcheridC-1517-2017tr_TR
dc.identifier.pubmed16440146tr_TR
dc.subject.wosCardiac & cardiovascular systemsen_US
dc.subject.wosPeripheral vascular diseaseen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ3 (Cardiac & cardiovascular systems)en_US
dc.wos.quartileQ4 (Peripheral vascular disease)en_US
dc.subject.scopusRat Heart; Ischemia; Xanthine Oxidaseen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.